ASLAN Collaborates with Singapore Institutes to Develop Cancer Drug

Singapore's ASLAN Pharma has formed an R&D collaboration with the Cancer Science Institute of Singapore (CSI) and National University Cancer Institute, Singapore (NCIS) to assess the potential of ASLAN003 as a treatment for hematologic cancers. ASLAN originally in-licensed global rights to the molecule as a treatment for rheumatoid arthritis from Spain's Almiral Pharma. In early 2016, ASLAN expanded the indications to include cancer. ASLAN is now listed on Taiwan's main board, and it is expected to stage a fundraising event soon. More details.... Share this with colleagues: // //